WO2011090224A1 - 의료용 품물의 약물 코팅 방법 - Google Patents
의료용 품물의 약물 코팅 방법 Download PDFInfo
- Publication number
- WO2011090224A1 WO2011090224A1 PCT/KR2010/000393 KR2010000393W WO2011090224A1 WO 2011090224 A1 WO2011090224 A1 WO 2011090224A1 KR 2010000393 W KR2010000393 W KR 2010000393W WO 2011090224 A1 WO2011090224 A1 WO 2011090224A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gel
- drug
- coating
- article
- coated
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
- A61B17/06166—Sutures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/005—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/14—Post-treatment to improve physical properties
- A61L17/145—Coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00526—Methods of manufacturing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
- A61B2017/00893—Material properties pharmaceutically effective
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2913—Rod, strand, filament or fiber
Definitions
- the present invention relates to a method of drug coating of a medical article.
- a thread that is generally used for medical purposes is a medical product used to join each other during the healing of tissues after suture of surgical parts of human tissues such as skin and blood vessels.
- a conventional suture to sew tissue, especially the torn areas of the skin, the growth of the cells in the stitched area, that is, the area that is perforated by the thread, is left unsightly scar. There was this.
- sutures with biocompatibility may act as foreign substances when present in the living body, causing inflammation in surrounding tissues.
- rejection of the suture may occur, and pus may be formed in the perforated area by the suture.
- the present invention has been made in view of the above-mentioned problems, and an object of the present invention is to provide a drug coating method of a medical article that facilitates coating of a drug.
- the drug coating method of the medical article to achieve the above object is a drug coating step of coating the drug on the surface of the article ( ⁇ ⁇ ) used for medical purposes; And a gel coating step of coating a drug-coated semi-solid gel on the surface of the article coated with the drug. Characterized in that it comprises a.
- the article is characterized in that the raw yarn.
- the gel is characterized in that gelatin (gelatin), dextran (dextran) and glyceraldehyde (glyceraldehyde) is mixed.
- the gelatin, dextran and glyceraldehyde is characterized in that the mixture in the aqueous solution.
- the gel is characterized in that gelatin (gelatin), dextran (dextran) and glutaraldehyde (glutaraldehyde) is mixed.
- gelatin dextran and glutaraldehyde is characterized in that it is mixed in the aqueous solution.
- a gel surface coating step of coating a material to smooth the surface of the gel It characterized in that it further comprises.
- the material to smooth the surface of the gel is characterized in that any one or more of polycaprolactone (PCL), polyglycolic acid (PGA), polylactic acid (PLA), polylactic-co-glycolic acid (PLGA) and polyethylene glycol (PEG) do.
- PCL polycaprolactone
- PGA polyglycolic acid
- PLA polylactic acid
- PLGA polylactic-co-glycolic acid
- PEG polyethylene glycol
- a material for smoothing the surface of the gel is further characterized in that the coating.
- the material for smoothing the surface of the gel may be any one or more of polycaprolactone (PCL), polyglycolic acid (PGA), polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), and polyethylene glycol (PEG). do.
- PCL polycaprolactone
- PGA polyglycolic acid
- PLA polylactic acid
- PLA polylactic-co-glycolic acid
- PEG polyethylene glycol
- the rate of release of the drug is characterized in that the gel is gelled (gelation) state.
- the gel is characterized in that the gel is coated on the article according to the concentration and temperature, the gelation time (gelation) is different.
- the drug coating method of a medical article is a gel coating step of coating a gel (gel) of the semi-solid state of the adhesive on the surface of the article used for medical purposes ( ⁇ ); And a drug coating step of coating a drug on the surface of the article coated with the gel. Characterized in that it comprises a.
- the drug coating step is characterized in that any one of the coating by soaking the product in the state of the gel-coated in the drug coating or spraying the drug by spray (spray).
- the gel is characterized in that gelatin (gelatin), dextran (dextran) and glyceraldehyde (glyceraldehyde) is mixed.
- the gelatin, dextran and glyceraldehyde is characterized in that the mixture in the aqueous solution.
- the gel is characterized in that gelatin (gelatin), dextran (dextran) and glutaraldehyde (glutaraldehyde) is mixed.
- gelatin dextran and glutaraldehyde is characterized in that it is mixed in the aqueous solution.
- a gel surface coating step of coating a material to smooth the surface of the gel It characterized in that it further comprises.
- the material to smooth the surface of the gel is characterized in that any one or more of polycaprolactone (PCL), polyglycolic acid (PGA), polylactic acid (PLA), polylactic-co-glycolic acid (PLGA) and polyethylene glycol (PEG) do.
- PCL polycaprolactone
- PGA polyglycolic acid
- PLA polylactic acid
- PLGA polylactic-co-glycolic acid
- PEG polyethylene glycol
- a material for smoothing the surface of the gel is further characterized in that the coating.
- the material for smoothing the surface of the gel may be any one or more of polycaprolactone (PCL), polyglycolic acid (PGA), polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), and polyethylene glycol (PEG). do.
- PCL polycaprolactone
- PGA polyglycolic acid
- PLA polylactic acid
- PLA polylactic-co-glycolic acid
- PEG polyethylene glycol
- the rate of release of the drug is characterized in that the gel is gelled (gelation) state.
- the gel is characterized in that the gel is coated on the article according to the concentration and temperature, the gelation time (gelation) is different.
- the drug coating method of the medical article in one aspect of the present invention to achieve this object is a mixing step of making a mixture of a gel (gel) and the drug for coating the surface of the article (medicine) used for medical purposes ; And mixture mixture coating the mixture on the surface of the article. Characterized in that it comprises a.
- the drug mixed in the mixture is characterized in that the water-soluble drug.
- the article is characterized in that the raw yarn.
- the gel is characterized in that gelatin (gelatin), dextran (dextran) and glyceraldehyde (glyceraldehyde) is mixed.
- the gelatin, dextran and glyceraldehyde is characterized in that the mixture in the aqueous solution.
- the gel is characterized in that gelatin (gelatin), dextran (dextran) and glutaraldehyde (glutaraldehyde) is mixed.
- gelatin dextran and glutaraldehyde is characterized in that it is mixed in the aqueous solution.
- a gel surface coating step of coating a material to smooth the surface of the gel It characterized in that it further comprises.
- the material to smooth the surface of the gel is characterized in that any one or more of polycaprolactone (PCL), polyglycolic acid (PGA), polylactic acid (PLA), polylactic-co-glycolic acid (PLGA) and polyethylene glycol (PEG) do.
- PCL polycaprolactone
- PGA polyglycolic acid
- PLA polylactic acid
- PLGA polylactic-co-glycolic acid
- PEG polyethylene glycol
- a material for smoothing the surface of the gel is further characterized in that the coating.
- the material for smoothing the surface of the gel may be any one or more of polycaprolactone (PCL), polyglycolic acid (PGA), polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), and polyethylene glycol (PEG). do.
- PCL polycaprolactone
- PGA polyglycolic acid
- PLA polylactic acid
- PLA polylactic-co-glycolic acid
- PEG polyethylene glycol
- the rate at which the drug is released varies according to the gelation state.
- the gel is characterized in that the gel is coated on the article according to the concentration and temperature, the gelation time (gelation) is different.
- the coating of the water-soluble drug is facilitated, and of course, a silk-like article and a material such as polypropylene. There is an effect that makes it easier to coat the drug on the article.
- the viscosity varies depending on the gelation state of the gel. The effect of controlling the rate at which the coated drug is ejected.
- FIG. 1 shows a state in which a suture constructed through an embodiment of the present invention is applied.
- Figure 2 shows a suture to which the first embodiment of the present invention is applied.
- Figure 3 shows a suture to which the second embodiment of the present invention is applied.
- Figure 4 shows a suture to which the third embodiment of the present invention is applied.
- FIG. 5 shows a flow according to the first embodiment of the present invention.
- FIG. 6 shows a flow according to a second embodiment of the present invention.
- FIG. 7 shows a flow according to a third embodiment of the present invention.
- the drug coating method of the medical article according to an embodiment of the present invention will be described with reference to FIGS. 1 to 7, and in the embodiment of the present invention, a medical seal which is one of medical articles will be described as an example.
- the present invention can be applied to artificial blood vessels and the like.
- a medical seal (hereinafter referred to as a 'suture') 10 according to the present invention is used for skin closure or as shown in FIG. 1 used to sew the skin to suture a portion opened by surgery or trauma. It is possible to be used to connect the arteries (A) and veins (V) of the patient for the purpose of anastomosis of artificial blood vessels.
- the aqueous state is gelled (Gelation) to harden to form a gel (g).
- gelatin is a kind of inducible protein obtained by treating collagen, which is a natural protein constituting animal skin, tendons and cartilage with hot water, and used as a hemostatic agent.
- Dextran is a complex and branched glucan composed of chains of various lengths, and is used as a substitute serum by dissolving about 6% in physiological saline by partially hydrolyzing it with raw materials such as syrups or acids.
- Glyceraldehyde (glyceraldehyde) is a compound produced during carbohydrate metabolism. It is a colorless crystalline solid. Glycerin, in which one hydroxide is converted to an aldehyde group, is soluble in water and alcohol, and appears as an intermediate in the reaction in vivo. .
- the gel (g) is configured to facilitate the coating of the drug (M) in the raw room (T), wherein the gelation time varies depending on the concentration of the components constituting the gel (g) and the reaction temperature. It is configured to be able to vary the release rate of the drug (M) depending on the gel state.
- the coating amount of the gel (g) to be coated on the raw chamber (T) by increasing the viscosity as it is gelled. For example, if a large amount of gel (g) is to be coated on the yarn (T), the gelation proceeds a lot, and the yarn (T) is coated using the gel (g) having a high viscosity, and the gel (g) is small. Gelling is just started to coat the suture 10 using gel (g) having a low viscosity.
- the process of making a gel (g) for applying to the embodiment of the present invention is made to facilitate coating the water-soluble drug (M) because it is usually made in the state of an aqueous solution, the suture (10) used for skin suture In the case of), it is preferable to coat a substance (M) which can suppress the occurrence of inflammation on the surface and the wound can be quickly healed without scarring.
- the drug (M) to be coated is preferably mixed with the gel (g) and coated with a mixture (G) to use a water-soluble drug, and the drug (M) and the gel (g) are different from each other.
- the drug (M) and the gel (g) are different from each other.
- bFGF basic fibroblast growth factor
- the gel (g) is rough in nature and may be inadequate for use for anastomosis of artificial blood vessels, in this case, polymers PCL (Polycaprolactone) and PGA, which are used to smooth the surface of the gel (g), are used.
- PCL Polycaprolactone
- PGA Polycaprolactone
- Polyglycolic acid Polyglycolic acid
- PLA Polylactic acid
- PLGA Polylactic-co-glycolic acid
- PEG Polyethylene glycol
- a drug (M) that can suppress vascular stenosis and inflammatory reactions as the drug (M) coated when used for anastomosis of artificial blood vessels.
- drugs (M) such as paclitaxel and rapamycin that can be inhibited.
- the drug coating method of the medical article according to the first embodiment of the present invention will be described with reference to the flowchart shown in FIG. 5, and the suture 10 using the drug coating method according to FIG. 5 is shown in FIG. 2. To explain.
- Dissolving the drug (M) for coating the surface of the raw room (T) in a solvent, the drug (M) used to suppress the occurrence of inflammation or to quickly narrow the wound without scarring substances or blood vessels narrowing The material and the like may be applicable, and it is configured to be able to coat a suitable drug (M) in the raw room (T) according to the use.
- step S501 to immerse the original chamber (T) in a solution in which the drug (M) is dissolved, the drug (M) is coated on the raw chamber (T) to form a drug coating layer.
- step S502 the drug (M) -coated yarn (T) is dried to complete the drug (M) coating.
- the drug (M) is coated and then dried to dry the drug (M) -coated yarn (T).
- the gel (g) is to be coated on the surface of the.
- a certain amount of gelatin is dissolved in water and incubated at 37 ° C, dextran and glaseraldehyde are mixed and dissolved in water, and then sufficiently mixed (vortex), and the two solutions are mixed at 37 ° C. Allow to gel by incubating at.
- step S511 the gel (g) in the aqueous solution is gelled over time, and in this case, it is possible to adjust the amount of the gel (g) coated on the raw chamber (T) according to the gelling state. Therefore, it is possible to adjust and use the amount of gel (g) coated on the yarn T by performing the dipping of the yarn T of step S513 by grasping the desired gelation state.
- the rate at which the drug (M) is released may vary depending on the gel state of the gel (g), and the gel (g) may be added to the chamber (T) according to the concentration and temperature of the components constituting the gel (g). The time to coat and gel may vary.
- the drug (M) is configured to the coating of the gel (g) to the surface.
- the gel (g) is coated on the surface of the raw yarn (T) is characterized in that the surface is rough, and further comprising the step of coating the surface of the gel (g) with a material to smooth the surface of the gel (g) It is also preferable to.
- the material for smoothing the surface of the gel (g) may include polycaprolactone (PCL), polyglycolic acid (PGA), polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), and polyethylene glycol (PEG).
- PCL polycaprolactone
- PGA polyglycolic acid
- PLA polylactic acid
- PLA polylactic-co-glycolic acid
- PEG polyethylene glycol
- step S513 the coating of the drug (M) is completed by drying the raw yarn (T) coated with the gel (g), and a suture (10) is formed as shown in FIG. You lose.
- steps S511 and S512 may be implemented even if the flow thereof is changed according to the convenience of the process.
- step S601 the gel (g) in the aqueous solution is gelled over time, and will be described with reference to the description in step S512 of the first embodiment.
- step S602 the gel (g) in the gelled state is immersed in the yarn (T) to coat the gel (g).
- step S603 the gel (g) coated on the raw chamber (T) is dried.
- step S604 In order to coat the drug (M) in the yarn (T) of the gel (g) coated state in step S604, dissolving the drug (M), the description will be omitted with reference to the first embodiment.
- step S611 a step in which the raw material T coated with the gel g is immersed in the solution in which the drug M is dissolved, will be omitted with reference to step S513 of the first embodiment.
- step S612 to dry the coated yarn (T) to the drug (M), the suture 10 as shown in Figure 3 is made.
- step S611 may be implemented even if the flow thereof is changed according to the convenience of the process.
- the drug coating method of the suture 10 according to the third embodiment of the present invention will be described with reference to the flowchart shown in FIG. 7, and the suture 10 using the drug coating method according to FIG. 7 is shown in FIG. 4. This will be explained with reference to the bar.
- Dissolving the drug (M) for coating the surface of the raw room (T) in a solvent, the drug (M) used to suppress the occurrence of inflammation or to quickly narrow the wound without scarring substances or blood vessels narrowing The material and the like may be applicable, and it is configured to be able to coat a suitable drug (M) in the raw room (T) according to the use.
- a water-soluble drug in order to be mixed with the gel (g) in the aqueous solution state to form a mixture (G) in step S702 described later.
- Dissolving the gel (g) for coating the surface of the raw yarn (T) in a solvent, gelatin, dextran and glaseraldehyde or glutaraldehyde is mixed to make a gel (g) in the aqueous solution state.
- step S701 a solution in which the drug (M) is dissolved and a gel (g) in an aqueous solution in step S711 are mixed to form a mixture (G). Coating the raw material (T) using the mixture (G) is performed. Make it possible.
- the mixture G mixed in step S702 is gelled with time, and it is possible to adjust the amount of gel g coated on the raw chamber T according to the gelling state.
- the raw material (T) When gelled to a suitable viscosity in step S703, the raw material (T) is immersed to form a coating of the mixture (G), wherein it is configured to be able to coat a suitable amount of gel (g) according to the viscosity of the gelation proceeded.
- the surface of the raw material (T) coated with the mixture (G) may be roughened by the gel (g), further comprising the step of further coating the surface of the gel (g) with a material that smoothes It is also preferable to add a substance which smoothes the surface of the gel (g) to the mixture (G).
- step S704 the raw material T coated with the mixture G is dried, so that the suture 10 having a shape as shown in FIG. 4 is completed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (17)
- 의료용으로 사용되는 품물(品物)의 표면에 약물이 코팅되는 약물코팅단계; 및상기 약물이 코팅된 상기 품물의 표면에 점착성이 있는 반고체 상태의 겔(gel)이 코팅되는 겔코팅단계; 를 포함하는 것을 특징으로 하는 의료용 품물의 약물 코팅 방법.
- 의료용으로 사용되는 품물(品物)의 표면에 점착성이 있는 반고체 상태의 겔(gel)이 코팅되는 겔코팅단계; 및상기 겔이 코팅된 상기 품물의 표면에 약물이 코팅되는 약물코팅단계; 를 포함하는 것을 특징으로 하는 의료용 품물의 약물 코팅 방법.
- 제2항에 있어서,상기 약물코팅단계는 상기 겔이 코팅된 상태의 상기 품물을 상기 약물에 담가서 코팅하거나 상기 약물을 스프레이(spray)로 분사하여 코팅하는 것 중 어느 하나인 것을 특징으로 하는 의료용 품물의 약물 코팅 방법.
- 의료용으로 사용되는 품물(品物)의 표면을 코팅하기 위한 겔(gel) 및 약물이 혼합된 혼합물질을 만드는 혼합단계; 및상기 혼합물질이 상기 품물의 표면에 코팅되는 혼합물질코팅단계; 를 포함하는 것을 특징으로 하는 의료용 품물의 약물 코팅 방법.
- 제4항에 있어서,상기 혼합물질에 혼합되는 상기 약물은 수용성 약물인 것을 특징으로 하는 의료용 품물의 약물 코팅 방법.
- 제1항, 제2항 및 제4항 중 어느 하나의 항에 있어서,상기 품물은 원(原)실인 것을 특징으로 하는 의료용 품물의 약물 코팅 방법.
- 제1항, 제2항 및 제4항 중 어느 하나의 항에 있어서,상기 겔은 젤라틴(gelatin), 덱스트란(dextran) 및 글리세르알데하이드(glyceraldehyde)가 혼합된 것을 특징으로 하는 의료용 품물의 약물 코팅 방법.
- 제7항에 있어서,상기 젤라틴, 덱스트란 및 글리세르알데하이드는 수용액 상태에서 혼합되는 것을 특징으로 하는 의료용 품물의 약물 코팅 방법.
- 제1항, 제2항 및 제4항 중 어느 하나의 항에 있어서,상기 겔은 젤라틴(gelatin), 덱스트란(dextran) 및 글루타르알데하이드(glutaraldehyde)가 혼합된 것을 특징으로 하는 의료용 품물의 약물 코팅 방법.
- 제9항에 있어서,상기 젤라틴, 덱스트란 및 글루타르알데하이드는 수용액 상태에서 혼합되는 것을 특징으로 하는 의료용 품물의 약물 코팅 방법.
- 제1항, 제2항 및 제4항 중 어느 하나의 항에 있어서,상기 품물의 표면에 상기 겔이 코팅되고 나서, 상기 겔의 표면을 매끄럽게 하는 물질이 코팅되는 겔표면코팅단계; 를 더 포함하는 것을 특징으로 하는 의료용 품물의 약물 코팅 방법.
- 제11항에 있어서,상기 겔의 표면을 매끄럽게 하는 물질은 PCL(polycaprolactone), PGA(polyglycolic acid), PLA(polylactic acid), PLGA(polylactic-co-glycolic acid) 및 PEG(polyethylene glycol) 중 어느 하나 이상인 것을 특징으로 하는 의료용 품물의 약물 코팅 방법.
- 제1항, 제2항 및 제4항 중 어느 하나의 항에 있어서,상기 품물의 표면에 상기 겔이 코팅되고 나서, 상기 겔의 표면을 매끄럽게 하는 물질이 더 코팅되는 것을 특징으로 하는 의료용 품물의 약물 코팅 방법.
- 제13항에 있어서,상기 겔의 표면을 매끄럽게 하는 물질은 PCL(polycaprolactone), PGA(polyglycolic acid), PLA(polylactic acid), PLGA(polylactic-co-glycolic acid) 및 PEG(polyethylene glycol) 중 어느 하나 이상인 것을 특징으로 하는 의료용 품물의 약물 코팅 방법.
- 제1항, 제2항 및 제4항 중 어느 하나의 항에 있어서,상기 겔이 겔화(gelation)된 상태에 따라 상기 품물에 상기 겔이 코팅되는 양의 정도를 조절하는 것이 가능한 것을 특징으로 하는 의료용 품물의 약물 코팅 방법.
- 제1항, 제2항 및 제4항 중 어느 하나의 항에 있어서,상기 겔이 겔화(gelation)된 상태에 따라 상기 약물이 방출되는 속도가 달라지는 것을 특징으로 하는 의료용 품물의 약물 코팅 방법.
- 제1항, 제2항 및 제4항 중 어느 하나의 항에 있어서,상기 겔은 농도 및 온도에 따라 상기 품물에 상기 겔이 코팅되어 겔화(gelation)되는 시간이 달라지는 것을 특징으로 하는 의료용 품물의 약물 코팅 방법.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201080000806.0A CN102740900A (zh) | 2010-01-21 | 2010-01-21 | 医用物品的药物涂覆方法 |
US12/809,054 US8399044B2 (en) | 2010-01-21 | 2010-01-21 | Method for coating medication on medical article |
PCT/KR2010/000393 WO2011090224A1 (ko) | 2010-01-21 | 2010-01-21 | 의료용 품물의 약물 코팅 방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2010/000393 WO2011090224A1 (ko) | 2010-01-21 | 2010-01-21 | 의료용 품물의 약물 코팅 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011090224A1 true WO2011090224A1 (ko) | 2011-07-28 |
Family
ID=44307023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/000393 WO2011090224A1 (ko) | 2010-01-21 | 2010-01-21 | 의료용 품물의 약물 코팅 방법 |
Country Status (3)
Country | Link |
---|---|
US (1) | US8399044B2 (ko) |
CN (1) | CN102740900A (ko) |
WO (1) | WO2011090224A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11958819B2 (en) | 2015-08-21 | 2024-04-16 | Johnson & Johnson Surgical Vision, Inc. | Compounds for optically active devices |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115385653A (zh) * | 2022-05-07 | 2022-11-25 | 华南理工大学 | 一种造纸脱墨污泥基凝胶材料及其制备方法与应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004033535A (ja) * | 2002-07-04 | 2004-02-05 | National Cardiovascular Center | 動脈瘤閉塞具 |
US6726923B2 (en) * | 2001-01-16 | 2004-04-27 | Vascular Therapies, Llc | Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts |
KR100496354B1 (ko) * | 2002-03-27 | 2005-06-20 | 서울산업대학교 산학협력단 | 생분해성 고분자 지지체층을 포함하는 하이브리드인공혈관 및 그의 제조 방법 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5788979A (en) * | 1994-07-22 | 1998-08-04 | Inflow Dynamics Inc. | Biodegradable coating with inhibitory properties for application to biocompatible materials |
WO2003061625A2 (en) * | 2002-01-18 | 2003-07-31 | Snyder Michael E | Sustained release ophthalmological device and method of making and using the same |
JP4624678B2 (ja) * | 2002-02-21 | 2011-02-02 | パイオニア・サージカル・オーソバイオロジックス,インコーポレイテッド | 架橋生物活性ヒドロゲルマトリックス |
US6919100B2 (en) * | 2003-01-22 | 2005-07-19 | Cordis Corporation | Method for coating medical devices |
DE102006051093B4 (de) * | 2006-10-25 | 2011-03-17 | Heraeus Kulzer Gmbh | Chirurgisches Nahtmaterial mit antimikrobieller Oberfläche und Verfahren zur antimikrobiellen Beschichtung chirurgischen Nahtmaterials |
KR20080078113A (ko) * | 2007-02-22 | 2008-08-27 | (주)액세스 플러스 | 약물이 코팅된 수술용 실 |
KR20110085700A (ko) * | 2010-01-21 | 2011-07-27 | 서울대학교산학협력단 | 의료용 품물의 약물 코팅 방법 |
-
2010
- 2010-01-21 CN CN201080000806.0A patent/CN102740900A/zh active Pending
- 2010-01-21 WO PCT/KR2010/000393 patent/WO2011090224A1/ko active Application Filing
- 2010-01-21 US US12/809,054 patent/US8399044B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6726923B2 (en) * | 2001-01-16 | 2004-04-27 | Vascular Therapies, Llc | Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts |
KR100496354B1 (ko) * | 2002-03-27 | 2005-06-20 | 서울산업대학교 산학협력단 | 생분해성 고분자 지지체층을 포함하는 하이브리드인공혈관 및 그의 제조 방법 |
JP2004033535A (ja) * | 2002-07-04 | 2004-02-05 | National Cardiovascular Center | 動脈瘤閉塞具 |
Non-Patent Citations (1)
Title |
---|
AKIHIKO,K. ET AL., ADVANCED DRUG DELIVERY REVIEWS, vol. 54, 2002, pages 53 - 77 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11958819B2 (en) | 2015-08-21 | 2024-04-16 | Johnson & Johnson Surgical Vision, Inc. | Compounds for optically active devices |
Also Published As
Publication number | Publication date |
---|---|
US20110183064A1 (en) | 2011-07-28 |
US8399044B2 (en) | 2013-03-19 |
CN102740900A (zh) | 2012-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8883190B2 (en) | Urologic devices incorporating collagen inhibitors | |
WO2021006426A1 (ko) | 생체모사 조직 접착성 하이드로젤 패치 및 이의 용도 | |
WO2014092239A1 (ko) | 콜라겐과 피브린이 혼합된 조직 실란트 및 그 제조방법 | |
WO2017039336A1 (ko) | 히알루론산염이 코팅된 고 기능성 봉합사의 제조방법 및 이로부터 제조된 고 기능성 봉합사 | |
WO2021091246A1 (ko) | 초기 방출 제어가 가능한 서방출성 미립구 및 이의 제조 방법 | |
JP2004533857A (ja) | 心膜の抗癒着性(anti−adhesion)パッチ | |
WO2017155328A1 (ko) | 생체 내 분해속도 및 물성 조절 가능한 생체적합성 돼지연골 유래 세포외기질 막 제조방법 및 상기 돼지연골 유래 세포외기질을 유효성분으로 함유하는 유착방지용 조성물 | |
WO2018026204A1 (ko) | 과산화칼슘을 이용한 서방형 산소 방출형 in situ 가교 하이드로젤의 제조방법 및 이의 생의학적 용도 | |
WO2022265368A1 (ko) | 점막 부착성과 팽윤성이 우수한 필름 형태의 유착방지용 조성물 | |
Younesi et al. | Effects of PDGF-BB delivery from heparinized collagen sutures on the healing of lacerated chicken flexor tendon in vivo | |
WO2018143552A2 (ko) | 탈모방지 또는 발모촉진용 주사용 조성물 | |
JP2022095767A (ja) | メッシュベースのインサイチュ架橋性組成物 | |
WO2022265367A1 (ko) | 유착방지용 조성물 | |
WO2011090224A1 (ko) | 의료용 품물의 약물 코팅 방법 | |
WO2021040493A1 (ko) | 온도감응형 조직유착 방지용 하이드로겔 조성물 및 그 제조방법 | |
WO2018056737A1 (ko) | 즉각적인 지혈능을 보유한 무출혈 주사바늘의 제조방법 | |
CN113577014A (zh) | 医疗器械、水凝胶及其制备方法与应用 | |
CN113171488B (zh) | 一种可吸收缝合线及其制备方法 | |
WO2020197104A1 (ko) | 히알루론산을 포함하는 봉합사 코팅용 조성물 및 이를 이용한 히알루론산이 코팅된 봉합사의 제조방법 | |
WO2023158092A1 (ko) | 위장관 내 지혈 및 상처 치료용 약학 조성물 | |
WO2022092585A1 (ko) | 생체적합성 필름 및 이의 제조방법 | |
WO2022019467A1 (ko) | 국소 지혈 파우더 조성물 및 이의 제조방법 | |
JP2009513290A (ja) | 強膜バックリングバンドとその製造方法 | |
KR20110085700A (ko) | 의료용 품물의 약물 코팅 방법 | |
WO2020106074A1 (ko) | 창상치료용 약학조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080000806.0 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12809054 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10844020 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10844020 Country of ref document: EP Kind code of ref document: A1 |